Strategic News: Digital Pathology Market to Hit $2.75B by 2030
Delray Beach, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) — The global digital pathology market, valued at US$1.30 billion in 2024 stood at US$1.46 billion in 2025 and is projected to advance at a resilient CAGR of 13.5% from 2025 to 2030, culminating in a forecasted valuation of US$2.75 billion by the end of the period. This rapid expansion is driven by increasing demand for telepathology, AI-powered diagnostics, and the ongoing digital transformation of healthcare diagnostics.
As pathology shifts from analog to digital workflows, healthcare organizations, research institutes, and life sciences companies are accelerating adoption to enhance efficiency, collaboration, and diagnostic precision.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844
What's Fueling the Digital Pathology Market Growth?
Rising Need for Telepathology: Pathologists can now remotely analyze slides, accelerating turnaround times and enabling real-time collaboration.
AI Integration: Artificial Intelligence is transforming image analysis, aiding in faster, more accurate diagnostics and predictive insights.
Strategic Collaborations: For example, the March 2024 partnership between Amazon Web Services (AWS) and Philips supports secure, cloud-based digital pathology platforms.
Chronic Disease Burden: Rising cancer cases and complex chronic conditions are pushing healthcare systems to adopt digital pathology for better diagnostics and treatment planning.
Market Segmentation Insights
By Type: Why is Human Pathology Leading?
The human pathology segment is experiencing the fastest growth due to: Increased demand for faster, accurate diagnostics
Chronic disease prevalence (especially cancer)
Benefits such as image sharing, remote collaboration, and reduced physical storage
Compared to traditional methods, digital pathology streamlines workflows and supports multidisciplinary decision-making.
By End User: Why Are Pharma & Biotech Companies Dominating?
In 2024, pharmaceutical and biotechnology companies led the market due to: Growing drug discovery and personalized medicine needs
Use of high-resolution imaging and automated screening for faster preclinical and clinical evaluations
Accelerated development of AI-assisted diagnostics
By Region: Why is North America Leading?
North America accounted for the largest market share in 2024, backed by: Advanced healthcare IT infrastructure
High R&D investments and strategic initiatives
Presence of leading pathology labs and academic institutions
A strong push for digital health technologies and early adoption in the US
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=844
People Also Ask: Top W-Questions for Digital PathologyQ. What is driving the digital pathology market growth?A. The combination of telehealth expansion, AI-powered image analysis, and demand for remote diagnostics is accelerating market growth.Q. How does digital pathology benefit hospitals and labs?A. It improves workflow efficiency, enables remote collaboration, speeds up diagnostics, and reduces operational costs.Q. Which companies are leading the digital pathology space?A. Top players include Danaher, Philips, Roche, Hamamatsu, Indica Labs, and PathAI, each advancing innovation and global adoption.Q. What challenges does the digital pathology market face?
A. Key hurdles include high initial investment costs, a shortage of skilled pathologists, and varied reimbursement policies across regions.
Key Companies Shaping the Digital Pathology Industry
Danaher Corporation (US)
Through its subsidiary Leica Biosystems, Danaher offers end-to-end solutions from biopsy to cancer diagnostics. Highlights include: 2023 partnership with Paige AI for next-gen AI-based diagnostics
Strategic collaboration with ESDIP to accelerate European adoption
AI-powered platforms for hospitals and labs to streamline workflows
Koninklijke Philips N.V. (Netherlands)
Philips leads the transition from analog to digital with: 15–20% per-case efficiency gains
Tools for real-time collaboration and remote consultations
Solutions implemented in over 300 institutions and 20+ labs globally
2024 partnership with AWS to integrate secure, cloud-based workflows
Other Prominent Players Include: Roche (Switzerland)
Indica Labs (US)
PathAI (US)
Fujifilm Holdings (Japan)
Hamamatsu Photonics (Japan)
3DHISTECH (Hungary)
Akoya Biosciences (US)
Proscia (US)
Sectra AB (Sweden)
Aiforia (Finland)
Hologic (US)
Glencoe Software (US)
XIFIN (US)
Motic Digital Pathology (US)
OptraSCAN (US)
Kanteron Systems (Spain)
Final Takeaway: Why Digital Pathology is the Future of DiagnosticsThe digital pathology market is no longer emerging — it's transforming the way diagnostics are conducted. With AI integration, collaborative platforms, and global partnerships, this industry is enabling faster, smarter, and more connected care.
As healthcare systems seek precision, scalability, and efficiency, digital pathology is fast becoming an essential part of the modern diagnostic ecosystem.
For more information, Inquire Now!
Explore Adjacent Healthcare Reports:
AI in Pathology Market
Computer Vision in Healthcare Market
Healthcare IT Market
Dental Digital X-ray Market
Tissue Diagnostics Market
Get access to the latest updates on Digital Pathology Companies and Digital Pathology Market Size
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Assured Guaranty Ltd (AGO) Q2 2025 Earnings Call Highlights: Record Highs in Book Value Amidst ...
Adjusted Book Value Per Share: $176.95 at the end of Q2 2025. Adjusted Operating Shareholders' Equity Per Share: $120.11 at the end of Q2 2025. Adjusted Operating Income Per Share: $4.21 for the first half and $1.01 for Q2 2025. US Municipal Issuance: 17% increase in par amount through June 30, 2025, compared to the previous year. Secondary Market Policies: Nearly $900 million written in the first half, including over $500 million in Q2 2025. Primary and Secondary Insured Municipal Par: Approximately $15 billion in the first half of 2025. New Issue Insured Par Sold: $14.1 billion in the first half, 30% more than the same period last year. New Issue Insured Par Sold in Q2: $9.5 billion, up 32% year-over-year. Primary Market Transactions: 474 new issues in the first half, 44% more than the previous year. Non-US Public Finance PVP: $14 million in the first half of 2025. Structured Finance PVP: $15 million in the first half of 2025. Adjusted Operating Income: $50 million or $1.01 per share in Q2 2025, compared to $80 million or $1.44 per share in Q2 2024. Net Earned Premiums and Credit Derivative Revenues: Increased by $5 million in Q2 2025. Net Investment Income: Increased by $8 million in Q2 2025. Insurance Segment Loss Expense: Increased by $27 million in Q2 2025. Share Repurchases: 1.5 million shares for $131 million at an average price of $85.03 per share in Q2 2025. Dividends: $19 million returned to shareholders in Q2 2025. Holding Company Liquidity: Cash and investments of $157 million as of June 30, 2025. Warning! GuruFocus has detected 8 Warning Signs with EMBC. Release Date: August 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Assured Guaranty Ltd (NYSE:AGO) achieved record highs in adjusted book value per share and adjusted operating shareholders' equity per share at the end of the second quarter. The company led the municipal bond insurance industry in par insured during the first half of 2025, capturing 64% of the insured par sold. Assured Guaranty Ltd (NYSE:AGO) significantly increased its secondary market policies, writing nearly $900 million in the first half of 2025. The company remains committed to its share repurchase program, with a target of $500 million for the year, and has already repurchased $296 million worth of shares. S&P Global Ratings and KBRA affirmed Assured Guaranty Ltd (NYSE:AGO)'s financial strength ratings, citing strong competitive position, excellent capital and earnings, and a well-diversified global underwriting strategy. Negative Points Second quarter 2025 adjusted operating income decreased to $50 million from $80 million in the second quarter of 2024. The company experienced an increase of $27 million in the Insurance segment loss expense, primarily due to additional reserves on certain UK regulated utility and US revenue exposures. Changes in the fair value of alternative investments and trading securities contributed to the decrease in adjusted operating income compared to the previous year. The average balance of the short-term investment portfolio declined, resulting in a decrease of $10 million in net investment income. Westchester Medical was added to the below investment grade list due to concerns about liquidity and potential headwinds from Medicaid and Medicare patients. Q & A Highlights Q: How does a lower interest rate environment impact Assured Guaranty's opportunities in primary and secondary public finance? A: Dominic Frederico, President and CEO, explained that a lower interest rate environment would decrease the premium volume as the basis for premium calculation would go down. It would also affect the insurance portfolio, which consists mostly of fixed income securities. However, the secondary market might not be impacted, and lower rates could lead to more issuers entering the market, potentially increasing business opportunities. Q: Can you provide more details on the increase in loss expenses and the exposure to non-US markets, particularly regarding Thames Water? A: Dominic Frederico noted that the company evaluates credits independently, and while some credits are downgraded, the top tier of the capital stack is well-protected. Loss reserves are calculated based on scenario analysis and probability weighting, and many credits do not result in actual losses. Regarding Thames Water, the company is comfortable with its position and expects the refinancing plan to be approved and implemented. Q: What is the impact of the recent changes in the Puerto Rico Oversight Board on restructuring procedures? A: Dominic Frederico expressed optimism that the changes could lead to improvements, as the previous board had not been effective in executing consensual deals. The process for appointing new members is still uncertain, but any change is expected to be positive. Q: How much contingent value instruments from earlier Puerto Rico restructuring does Assured Guaranty still hold, and how does this relate to PREPA's ability to repay? A: Dominic Frederico stated that the company holds about $117 million in contingent value instruments, which have performed well. The company believes PREPA has the ability to repay its debt, and the administrative expense claim continues to grow, indicating a positive outlook for resolving disputes and reaching a consensual agreement. Q: What led to Westchester Medical being added to the BIG list, and what are the expectations for its turnaround? A: Benjamin Rosenblum, CFO, explained that the downgrade was due to liquidity concerns and potential headwinds from Medicaid and Medicare. However, the company has a positive view on the turnaround possibilities and is working with the facility to address the issues. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Bloomberg
18 minutes ago
- Bloomberg
Top German Pharma Boehringer Wins US Approval for Cancer Drug
Boehringer Ingelheim GmbH won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company. The drug, called zongertinib, can now be used on patients with HER2-mutant non-small cell lung cancer who have already received chemotherapy, according to a statement. The patients, whose tumors either can't be completely surgically removed or whose cancer has already spread, currently have few options and low survival rates.
Business Upturn
22 minutes ago
- Business Upturn
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:
